Daratumumab (Dara), a humanized IgG1K mAb approved by the FDA for use in relapsed MM (Lokhorst et al., 2015), is targeted to the receptor cluster of differentiation 38 (CD38) upregulated in malignant plasma cells but remained low-level expression by surrounding hematopoietic cells. This evidence concerns the gene CD38 and Miyoshi myopathy.